Today's focus

[Zheshang Bank: Governor Zhang Rongsen resigns due to personal reasons]

Zheshang Bank announced that Zhang Rongsen resigned as the company's executive director and governor due to personal reasons. These resignations took effect when the resignation report was delivered to the company's board of directors. Chairman Lu Jianqiang will perform the duties of governor on his behalf until the date the qualifications of the new governor appointed by the board of directors are approved by the China Financial Supervisory and Administration. Currently, the company's various business activities are being carried out normally, and this matter will not have a significant impact on the company's daily operation and management work.

[4-board Yashi Optoelectronics: Currently, the company's products are not used in AI glasses-related fields and no relevant agreements or orders have been signed]

Yashi Optoelectronics announced abnormal fluctuations in stock trading. Recently, the “AI glasses” concept attracted market attention, and some media and other platforms reported on the company. The company explained the above situation as follows: The company has VR product-related design and manufacturing capabilities, and the company's VR related products are VR application products with liquid crystal display modules, which are mainly used in cinemas, etc. The company has had no orders for VR related products in the past year, which has no impact on the company's current revenue. Currently, the company's products are not used in AI glasses-related fields, and no relevant agreements or orders have been signed. Investors are reminded to invest rationally and pay attention to investment risks.

[2 consecutive boards, Shenzhen Huaqiang: The company is one of Hisilicon's main authorized agents, and the progress of new product promotion is uncertain]

Shenzhen Huaqiang announced abnormal stock trading fluctuations. Regarding the recent cooperation between the company and Hisilicon, the company has previously clearly explained in the Shenzhen Stock Exchange Interactive Easy and Investor Relations Activity Record Form. It is now explained once again as follows: The company's main business is authorized distribution of electronic components, and has established long-term friendly cooperative relationships with many well-known international and domestic original manufacturers. The company is one of the main authorized agents of Hisilicon. As Hisilicon launches new products one after another, the company will step up the development and promotion of application solutions for Hisilicon products to promote the market expansion of Hisilicon products. At the same time, the company reminds investors that the promotion progress of new products is uncertain, and the impact on the company's performance remains to be seen. Investors are invited to make careful decisions and pay attention to investment risks.

[*ST Chaohua: The company's stock will be delisted on August 19]

*ST Chaohua announced that the company's stock listing has been terminated by the Shenzhen Stock Exchange and will be delisted on August 19.

Fixed Increase & Financing & Repurchase

[Superstar Agriculture and Animal Husbandry: Plans to buy back shares with 0.1 billion yuan to 0.2 billion yuan]

Superstar Agriculture and Animal Husbandry announced that the company plans to use 0.1 billion yuan to 0.2 billion yuan to repurchase shares for employee stock ownership plans or share incentives. The share repurchase price will not exceed 25.21 yuan/share.

Stock price changes

[2-board Skyworth Digital: The company's AI glasses business is still in the R&D testing stage and there are currently no orders] Skyworth Digital issued an announcement of abnormal stock trading fluctuations. Based on abnormal fluctuations in the company's stock trading price, the company noticed that AI glasses products and applications and related industry chains have received a lot of attention from the market recently. According to the company's verification, the company's AI glasses business is still in the R&D testing stage. Currently, there are no orders, and no revenue has been achieved. There is great uncertainty about the subsequent expansion of this business. Investors are kindly requested to pay attention to investment risks, make rational decisions, and invest prudently.

[2 consecutive board Asia Pacific Pharmaceutical: Important matters that the company should not disclose and did not disclose] Asia Pacific Pharmaceutical announced that the cumulative deviation value of the closing price increase of the company's shares exceeded 20% for two consecutive trading days on August 15 and August 16, 2024, which is an abnormal fluctuation in stock trading. After verification, there was no information disclosed by the company in the early stages that needed to be corrected or added. It was not found that the public media had recently reported any major undisclosed information that may or has had a significant impact on the company's stock trading price, and there have been no major changes in the company's business situation or internal and external business environment recently. The company, controlling shareholders and actual controllers have no significant matters relating to the Company that should have been disclosed but not disclosed.

Operation & Performance

[Ganneng shares: net profit of 0.339 billion yuan in the first half of the year increased by 150.67% year-on-year]

Ganneng Co., Ltd. disclosed its semi-annual report. The company achieved operating income of 3.078 billion yuan in the semi-annual year of 2024, a year-on-year decrease of 10.05%; net profit to mother of 0.339 billion yuan, an increase of 150.67% over the previous year; and basic earnings per share of 0.35 yuan. By the end of the reporting period, the company had a total installed capacity of 3.9471 million kilowatts, with a cumulative total power generation capacity of 7.292 billion kilowatt-hours, a decrease of 9.88% over the same period last year. During the reporting period, the company's thermal power generation capacity was 6.922 billion kilowatt-hours, a year-on-year decrease of 12.12%; the company's hydroelectric power generation capacity was 0.214 billion kilowatt-hours, an increase of 42.2% over the previous year; and the company's photovoltaic power generation capacity was 0.156 billion kilowatt-hours, an increase of 139.27% year on year.

[Shengxiang Biotech: Net profit increased 70.93% year-on-year in the first half of the year, and plans to pay 10 to 2.5 yuan]

Shengxiang Biotech disclosed its semi-annual report. In the first half of the year, it achieved operating income of 0.717 billion yuan, an increase of 67.63% year on year; net profit to mother of 0.157 billion yuan, up 70.93% year on year; and basic earnings per share of 0.27 yuan. The company plans to pay a cash dividend of 2.5 yuan (tax included) for every 10 shares. During the reporting period, the company made great strides in technology, products and market layout in various key fields such as respiratory tract, motherhood, hematology, and sequencing, and gradually entered a stage of volume growth.

[Huiquan Beer: Net profit of 31.5267 million yuan in the first half of the year increased by 41.56% year-on-year]

Huiquan Brewery released its semi-annual report. In the first half of the year, it achieved operating income of 0.348 billion yuan, an increase of 0.33% over the previous year; net profit of 31.5267 million yuan, an increase of 41.56% over the previous year; and basic earnings per share of 0.13 yuan. During the reporting period, the company achieved beer sales of 0.1192 million kiloliters, an increase of 0.24% over the previous year. During the reporting period, the gross margin of the company's products increased by 2.60 percentage points over the previous year.

[Jinmembrane Technology: Net profit of 1.4043 million yuan in the first half of the year reversed the loss year on year]

According to the semi-annual report, Jinmen Technology revealed that the company achieved operating income of 0.133 billion yuan for the first half year of 2024, an increase of 42.81% year on year; realized net profit of 1.4043 million yuan to mother, reversed losses year on year; and basic income per share was 0.005 yuan. During the reporting period, the company continued to increase market development, order signing and delivery of products and equipment centered on separation membranes and HPS efficient clarification tanks. Sales revenue of separation membranes and water treatment equipment increased over the same period last year; accelerated the development, signing and implementation of engineering projects mainly integrating separation membranes and water treatment systems, and increased water treatment project revenue over the same period last year. During the reporting period, the company's operating fundamentals gradually stabilized.

[Zhaofeng shares: net profit in the first half of the year fell 13.22% year on year, and plans to pay 10 yuan to 7 yuan]

Zhaofeng Co., Ltd. disclosed its semi-annual report. The company achieved operating income of 0.325 billion yuan in the semi-annual year of 2024, a year-on-year decrease of 3.64%; net profit to mother of 66.3079 million yuan, a year-on-year decrease of 13.22%; and basic earnings per share of 0.93 yuan. The company plans to pay a cash dividend of 7 yuan (tax included) for every 10 shares.

other

[Amaton: The matter of terminating the purchase of 100% shares in Fengyang Silicon Valley Intelligence Co., Ltd.]

Amaton announced that the company originally intended to purchase 100% of Fengyang Silicon Valley Intelligence Co., Ltd.'s shares by issuing shares and paying cash, while also raising supporting capital. Taking into account the current state of the photovoltaic industry, capital market and related policy changes, after careful analysis, the company plans to terminate the transaction and sign relevant termination agreements with the parties to the transaction.

[Bailey Tianheng: BL-B01D1 completed the first patient enrollment in phase III clinical trial for recurrent small cell lung cancer]

Baili Tianheng announced that the phase III clinical trial of the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy developed independently by the company for recurrent small cell lung cancer that has failed platinum-containing chemotherapy and anti-PD-1/PD-L1 monoclonal antibody treatment has recently completed the first patient enrollment.